FI945553A0 - Peptidien suoloja karboksipäätteisten polyestereiden kanssa - Google Patents

Peptidien suoloja karboksipäätteisten polyestereiden kanssa

Info

Publication number
FI945553A0
FI945553A0 FI945553A FI945553A FI945553A0 FI 945553 A0 FI945553 A0 FI 945553A0 FI 945553 A FI945553 A FI 945553A FI 945553 A FI945553 A FI 945553A FI 945553 A0 FI945553 A0 FI 945553A0
Authority
FI
Finland
Prior art keywords
carboxy
peptides
salts
polyesters
terminal
Prior art date
Application number
FI945553A
Other languages
English (en)
Swedish (sv)
Other versions
FI945553A (fi
FI112603B (fi
Inventor
Francis Gowland Hutchinson
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of FI945553A0 publication Critical patent/FI945553A0/fi
Publication of FI945553A publication Critical patent/FI945553A/fi
Application granted granted Critical
Publication of FI112603B publication Critical patent/FI112603B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
FI945553A 1992-05-28 1994-11-25 Menetelmä peptidikationin ja polyesterianionin käsittävän koostumuksen valmistamiseksi FI112603B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB@@@@A GB9211268D0 (en) 1992-05-28 1992-05-28 Salts of basic peptides with carboxyterminated polyesters
PCT/GB1993/001079 WO1993024150A1 (en) 1992-05-28 1993-05-25 Salts of peptides with carboxy-terminated polyesters

Publications (3)

Publication Number Publication Date
FI945553A0 true FI945553A0 (fi) 1994-11-25
FI945553A FI945553A (fi) 1995-01-25
FI112603B FI112603B (fi) 2003-12-31

Family

ID=10716132

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945553A FI112603B (fi) 1992-05-28 1994-11-25 Menetelmä peptidikationin ja polyesterianionin käsittävän koostumuksen valmistamiseksi

Country Status (33)

Country Link
US (3) US5889110A (fi)
JP (1) JPH08501064A (fi)
KR (1) KR100293882B1 (fi)
AT (1) AT407702B (fi)
AU (1) AU682310B2 (fi)
BE (1) BE1006143A3 (fi)
CA (1) CA2136751C (fi)
CH (2) CH690491A5 (fi)
CZ (1) CZ292449B6 (fi)
DE (2) DE4392401T1 (fi)
DK (1) DK176134B1 (fi)
ES (1) ES2107357B1 (fi)
FI (1) FI112603B (fi)
FR (1) FR2691631B1 (fi)
GB (3) GB9211268D0 (fi)
GR (1) GR1001550B (fi)
HK (1) HK133097A (fi)
HU (1) HUT70177A (fi)
IE (1) IE74715B1 (fi)
IL (1) IL105710A (fi)
IT (1) IT1271139B (fi)
LU (1) LU88559A1 (fi)
MC (1) MC2330A1 (fi)
NL (1) NL195056C (fi)
NO (1) NO311006B1 (fi)
NZ (1) NZ252268A (fi)
RU (1) RU2152225C1 (fi)
SE (1) SE501970C2 (fi)
SG (1) SG44645A1 (fi)
SK (1) SK280320B6 (fi)
TW (1) TW223018B (fi)
WO (1) WO1993024150A1 (fi)
ZA (1) ZA933358B (fi)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
EP1353701B1 (en) * 2000-10-31 2011-12-21 PR Pharmaceuticals, Inc. Methods for producing compositions for enhanced delivery of bioactive molecules
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6873915B2 (en) * 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
DK1429731T3 (da) * 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
CN101785861B (zh) * 2001-10-19 2014-08-13 爱德士实验室公司 用于药理活性化合物的可控释放的可注射组合物
NZ533436A (en) * 2001-11-14 2007-10-26 Alza Corp Catheter injectable depot compositons and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
EP1344520B1 (en) * 2002-03-15 2007-10-03 Alrise Biosystems GmbH Microparticles and method for their production
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
DK1532985T3 (en) 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN1684663A (zh) * 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
AU2002359397B2 (en) * 2002-07-31 2009-01-29 Durect Corporation Injectable depot compositions and uses thereof
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
JP2006508127A (ja) 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SG192300A1 (en) 2003-01-28 2013-08-30 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
DK1610822T4 (en) * 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
CA2526099C (en) * 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
WO2005034852A2 (en) 2003-08-26 2005-04-21 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
CA2548822C (en) 2003-12-08 2015-08-11 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8945598B2 (en) 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
ITMI20061538A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
US20090163603A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends
EP2237770A4 (en) 2007-12-26 2011-11-09 Gel Del Technologies Inc BIOCOMPATIBLE PROTEIN PARTICLES, PARTICLE DEVICES AND METHODS THEREOF
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
JP5855568B2 (ja) 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
BR112012014947A2 (pt) * 2009-12-22 2019-09-24 Takeda Pharmaceuticals Co formulação de liberação prolongada,e, método para produzir a formulação de liberação prolongada
DE102010003615A1 (de) 2010-04-01 2011-10-06 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Herstellung eines Drug-Delivery-Systems auf der Basis von Polyelektrolytkomplexen
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
UY33465A (es) * 2010-06-25 2012-01-31 Takeda Pharmaceutical Formulacion de liberacion sostenida
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012250776B2 (en) 2011-05-04 2017-06-15 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
KR101467275B1 (ko) * 2011-12-19 2014-12-02 주식회사 삼양바이오팜 분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
ES2804702T3 (es) * 2013-03-04 2021-02-09 Besins Healthcare Lu Sarl Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo unidas a partículas de portador
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
EP4331670A3 (en) 2015-01-07 2024-05-29 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
US20210154147A1 (en) * 2018-10-19 2021-05-27 Ac Pharmaceuticals Co., Ltd. Preparation method of sustained-release microparticles
CN110954491B (zh) * 2019-12-09 2022-11-15 北京博恩特药业有限公司 用于测量醋酸戈舍瑞林缓释植入剂体外溶出度的方法
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
AU2022323754A1 (en) 2021-08-05 2024-02-08 Medincell S.A. Pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5005602A (en) * 1985-12-24 1991-04-09 Dover Corporation Poppet valve assembly
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CH679207A5 (fi) * 1989-07-28 1992-01-15 Debiopharm Sa
EP0489743A1 (en) * 1990-07-03 1992-06-17 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

Also Published As

Publication number Publication date
WO1993024150A1 (en) 1993-12-09
GB2282066B (en) 1996-11-06
CA2136751A1 (en) 1993-12-09
GB2282066A (en) 1995-03-29
US20020198315A1 (en) 2002-12-26
ES2107357B1 (es) 1998-10-16
ES2107357A1 (es) 1997-11-16
IL105710A0 (en) 1993-09-22
IE74715B1 (en) 1997-07-30
FR2691631A1 (fr) 1993-12-03
SG44645A1 (en) 1997-12-19
GR1001550B (el) 1994-04-29
SE9404115L (sv) 1994-11-28
ITMI931099A1 (it) 1994-11-27
US5889110A (en) 1999-03-30
LU88559A1 (fr) 1995-04-05
NZ252268A (en) 1996-12-20
AU682310B2 (en) 1997-10-02
DK135394A (da) 1994-11-28
TW223018B (en) 1994-05-01
HUT70177A (en) 1995-09-28
DK176134B1 (da) 2006-09-18
IE930358A1 (en) 1993-12-01
FR2691631B1 (fr) 1995-06-09
GB9423366D0 (en) 1995-01-25
SK280320B6 (sk) 1999-11-08
NO944535L (no) 1995-01-25
SK143494A3 (en) 1995-07-11
CH688911A5 (de) 1998-05-29
ZA933358B (en) 1994-09-15
HK133097A (en) 1997-10-24
BE1006143A3 (fr) 1994-05-24
ITMI931099A0 (it) 1993-05-27
CH690491A5 (de) 2000-09-29
DE4392401B4 (de) 2007-05-16
GB9211268D0 (en) 1992-07-15
JPH08501064A (ja) 1996-02-06
RU2152225C1 (ru) 2000-07-10
FI945553A (fi) 1995-01-25
CZ293794A3 (en) 1995-03-15
IT1271139B (it) 1997-05-27
IL105710A (en) 2001-03-19
GB9309645D0 (en) 1993-06-23
NO944535D0 (no) 1994-11-25
FI112603B (fi) 2003-12-31
DE4392401T1 (de) 1997-07-24
SE9404115D0 (sv) 1994-11-28
US6034175A (en) 2000-03-07
CA2136751C (en) 2006-10-31
SE501970C2 (sv) 1995-07-03
HU9403371D0 (en) 1995-02-28
NL195056C (nl) 2003-07-01
ATA901993A (de) 2000-10-15
KR100293882B1 (ko) 2001-09-17
CZ292449B6 (cs) 2003-09-17
NL9320034A (nl) 1995-04-03
MC2330A1 (fr) 1994-05-31
RU94046097A (ru) 1996-09-20
AU4084793A (en) 1993-12-30
AT407702B (de) 2001-05-25
NO311006B1 (no) 2001-10-01

Similar Documents

Publication Publication Date Title
FI945553A0 (fi) Peptidien suoloja karboksipäätteisten polyestereiden kanssa
FI935223A (fi) Rake-mottagare med selektiv kombinering av straolar
DE69220382D1 (de) Verwendung von Peptidderivaten
FI930376A0 (fi) Tillslutningsanordning av gaengtyp med saekringsorgan
DK223390D0 (da) Modificerede hydrofile polyestere
BR9205719A (pt) Preparaçao de filamentos delgados de polièster
IT8647723A0 (it) Procedimento per la fabbricazione di articoli in poliesteri parzialmente cristallini
NO924885D0 (no) Fremgangsmaate for fremstilling av syntesegass
FI934014A0 (fi) Tillvaratagning av rikligt med syre innehaollande gas i ozonblekningsprocess
ZA928979B (en) Novel aminoalkanephosphinic acids and salts thereof
DE69320763D1 (de) Spannungsfühler
DE69213637D1 (de) Herstellung von 2-Hydroxymandelsäuren und 2-Hydroxybenzaldehyden
NO922315D0 (no) Sproeyte for tilfoersel av medisin
FI932658A0 (fi) Foerfarande foer framstaellning av viskosfibrer med bandformade tvaersnitt
FI925493A0 (fi) Rumselementsystem foer ersaettning av vaotutrymmen med tillfaelligutrymmeni samband med byggnadsarbeten
NO940131D0 (no) Salter av 4-pyrimidinon-derivater for framasoeytisk anvendelse
DE59409126D1 (de) Wachstums-Differenzierungsfaktor der TGF-B Familie
KR900008077A (ko) 폴리에스터 혼섬사의 제조방법
FI921063A (fi) Foerfarande foer reparering av en stolpes roetskadade nebre aenda i en byggnad med traestomme
FI942397A0 (fi) Menetelmä 2-amino-3-hydroksihappojen valmistamiseksi
KR920020733U (ko) 화장품용기의 장식부착구조
NO923902L (no) Ionetoporetisk tilfoersel av medikamenter
PL289767A1 (en) Method of obtaining modified polyesters
NO920022D0 (no) Umettede hydroksyalkylkinolinsyrer
KR900009758A (ko) 폴리에스테르의 제조방법